956907-14-5

Basic information

• Product Name: 6-((6-broMo-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)Methyl)quinoline
• Synonyms: 6-((6-broMo-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)Methyl)quinoline
• CAS NO: 956907-14-5
• Molecular Formula: C₁₄H₉BrN₆
• Molecular Weight: 341.16546
• Mol File: 956907-14-5.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-((6-broMo-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)Methyl)quinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 6-((6-broMo-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)Methyl)quinoline(956907-14-5)
• EPA Substance Registry System: 6-((6-broMo-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)Methyl)quinoline(956907-14-5)

Safety Data

• Hazardous Substances Data: 956907-14-5(Hazardous Substances Data)

Upstream product

• 23395-72-4 quinoline-6-carbonitrile 
• 956907-13-4 6-bromo-N²-(quinolin-6-ylmethyl)pyrazine-2,3-diamine 
• 110-46-3 isopentyl nitrite 
• 5332-25-2 6-bromoquinoline 
• 872047-71-7 2-(quinolin-6-ylmethyl)isoindoline-1,3-dione 
• 38896-30-9 6-(methoxycarbonyl)quinoline 
• 100516-88-9 6-(hydroxymethyl)quinoline 
• 99071-54-2 quinolin-6-ylmethanamine 

Relevant articles and documents

Discovery of small-molecule fluorescent probes for C-Met

C-mesenchymal-epithelia transition factor (c-Met) is highly expressed in various solid tumors such as gastric cancer, liver cancer, and lung cancer, playing a pivotal role in the growth, maintenance, and development of different tumor cells. In this study, three small-molecule fluorescent probes (5, 11, 16) targeting c-Met were developed, and their design strategies were also initially explored. In general, the fluorescence properties of the probes themselves could meet the imaging requirements, and they have shown sufficient inhibitory activities against c-Met, especially probe 16, reflecting the targeting and acceptance. Also, fluorescence polarization assays and flow cytometry analysis verified the binding between the probes and c-Met. Cell imaging confirmed that these probes could be used to label c-Met on living cells. It is of positive significance for the development of c-Met kinase inhibitors and tumor pathology research.

Discovery of (S)-1-(1-(Imidazo[1,2- a ]pyridin-6-yl)ethyl)-6-(1-methyl-1 H -pyrazol-4-yl)-1 H -[1,2,3]triazolo[4,5- b ]pyrazine (Volitinib) as a Highly Potent and Selective Mesenchymal-Epithelial Transition Factor (c-Met) Inhibitor in Clinical Development for Treatment of Cancer

HGF/c-Met signaling has been implicated in human cancers. Herein we describe the invention of a series of novel triazolopyrazine c-Met inhibitors. The structure-activity relationship of these compounds was investigated, leading to the identification of compound 28, which demonstrated favorable pharmacokinetic properties in mice and good antitumor activities in the human glioma xenograft model in athymic nude mice.

HETEROCYCLIC HYDRAZONE COMPOUNDS AND THEIR USES TO TREAT CANCER AND INFLAMMATION

The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).